Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Markers for CYP3A Activity in Healthy Koreans
NCT02328443Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of midazolam, sponsored by Seoul National University Hospital. Primary endpoint: Quantitation of endogenous metabolites at 24 hours. Started Jan 2014; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on NCT02328443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328443.